Abstract Background: Interstitial lung disease (ILD) is a frequent extra-articular manifestation of RA and can cause significant morbidity and mortality.
Introduction
Rheumatoid arthritis (RA) is one of the most common and serious forms of arthritis. It is a chronic inflammatory autoimmune disease, mainly characterized by inflammation of the lining synovium of the joints with long-term joint destruction, leading to severe disability and premature mortality [1] . The presence of auto antibodies, such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) can precede the clinical manifestation of RA by many years [2] .
It has been estimated that nearly 50% of RA patients develop some form of respiratory abnormality during their lifetime. While there are numerous pulmonary complications associated with RA, the most debilitating remains rheumatoid arthritis-associated interstitial lung disease (RA-ILD) [3] . Advancements in imaging technology have improved our ability to diagnose RA-ILD, and what once was thought to be a relatively rare complication is now suspected to affect 20-30% of RA patients [4] .
Over the last decade, the optimal use of disease modifying anti rheumatic drugs (DMARDs), in particular the anchor DMARD methotrexate (MTX) [5] , and the availability of new biologic agents [6] , have dramatically enhanced the success of RA management. However patients with RA may develop lung disease from these medications, with reports of pulmonary toxicity from gold [7] , penicillamine [8] , bucillamine [9] , leflunomide [10] , methotrexate [11] , sulfasalazine [12] , and infliximab [13] . MTX is the first choice DMARD for RA [14] , which is a folic acid antagonist that inhibits cellular reproduction by causing an acute intracellular deficiency of folate coenzymes. Two forms of interstitial lung disease related to MTX therapy have been reported, life-threatening acute MTX pneumonitis, which is the most feared complication [15] and chronic pulmonary fibrosis. As recently reported, these side effects may be triggered by genetic factors; however, hypersensitivity is probably responsible for most cases of pneumonitis associated with MTX, particularly in the cases with established lung disease [16] .
There is growing awareness that some forms of RA-ILD transition from asymptomatic or ''subclinical'' stages before an eventual clinical diagnosis. Subclinical ILD involves groups of patients who have specific radiological, physiological and in some cases histo-pathological abnormalities but are either asymptomatic or have symptoms that have not been attributed to ILD [17, 18] .
Little work has been conducted to show the preclinical and early radiological and functional manifestations in asymptomatic RA patients. So this study was done to characterize and define the frequency of radiological and functional abnormalities capable of identifying ''subclinical'' RA-ILD with particular concern to the effect of MTX therapy.
Patients and methods
This study was done at Alrashid Respiratory center and Respiratory, Rheumatology& Radiology departments, Farwaniya Hospital, Ministry of Health, State of Kuwait. 60 Kuwaiti patients with Rheumatoid arthritis (RA) were recruited in the period between November 2012 and February 2014 and were diagnosed with definite RA according to the 2010 criteria of American College of Rheumatology [1] . All patients had no chest symptoms or signs at time of inclusion. They were classified into two groups according to the therapy use; Group (1) included 35 patients (58.3%) who received only MTX therapy and Group (2) included 25 patients (41.7%) who received only non-steroidal antiinflammatory drugs (or cyclo-oxygenase enzyme-2 'COX-2' inhibitors). All patients were also further classified into categories of RA-ILD and RA-no ILD based on HRCT abnormalities consisting of ground glass opacities (GGO), septal lines, reticulations, subpleural fibrosis, traction bronchiectasis, architectural distortion, and/or honeycombing. The study was approved by the ethics committee of the Ministry of Health, State of Kuwait and the patients were included in the study after giving their informed consent after explanation of the purpose and procedures of the study.
All enrolled patients were subjected to complete history taking and examination including duration of disease, smoking status and drug therapy. Assessment of disease activity was done using the Simplified Disease Activity Index (SDAI) [19] , which is the numerical sum of five outcome parameters, tender and swollen joint count scores (based on a 28 points joint assessment), patient and physician global assessment of disease activity (visual analog scale (VAS) 0-10 cm) and level of C-reactive protein (normal <1 mg/dl). A score of more than 26 points denotes high disease activity, from 11 to 26 points indicates moderate disease activity and less than 11 denotes low disease activity and less than 3 means disease remission [11] . Laboratory investigations were done including complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Rheumatoid factor (RF) (IgG Enhanced ELISA, ImmuLisa, Euro Diagnostica, Malmo, Sweden), and anti-cyclic citrullinated peptide (anti-CCP) (ELISA Kit, GenWay Biotech. Inc, San Diego, USA).
Complete pulmonary function testing (PFT) were made using Jaeger Masterscreen PFT system (CareFusion, Germany) and according to American Thoracic Society recommendations [12] . Measurement of the diffusing capacity for carbon monoxide (DL CO , mL/min/mmHg) was performed using Real-time DL CO gas analysis. We recorded the proportions of patients presenting reduced total lung capacity (TLC) or reduced forced vital capacity (FVC) lower than 80% of predicted with a normal or increased ratio between forced expiratory volume in one second and FVC, as well as DL CO lower than 75% of predicted.
All patients were subjected to plain chest X-ray and highresolution computed tomography (HRCT) scan, which was graded using a modified quantitative scale [20] . The findings were assigned as 0; normal, 1; Minimal disease (3-4 septal lines), 2; Mild (P5 septal lines, reticulations, subpleural cysts, and ground glass opacities), 3; Moderate disease (grade 2 findings and traction bronchiectasis, peri-bronchovascular thickening or tracheal retraction with one-third to two-thirds lung involvement), or 4; Severe (grade 2 or 3 findings with more than two-thirds lung involvement).
Exclusion criteria
All patients under steroids or biological therapy, patients known to have pulmonary or cardiovascular diseases, patients with obstructive or mixed pulmonary dysfunction and those with active infection, HIV/AIDS, and malignancy were excluded from the study.
Statistical analysis
Statistical analysis was done using statistical software 'SPSS version 10.0' (SPSS Inc, Chicago, IL, USA). Normally distributed variables were summarized as mean with standard deviation and compared between the two groups using Student's t-test. Chi-squared testing and Fisher exact test was applied to compare the ordinal variables. For all analyses, p value <0.05 was considered statistically significant and p value <0.001 was considered highly statistically significant. Multinomial logistic regression analysis was performed to assess the relationship between the presence of ILD in patients with RA (as a response variable) and a set of predictor variables. The regression coefficients were actually computed by a software program in terms of relative risk ratio and the 95% confidence interval (95% CI).
Results
This study included 60 RA patients without respiratory symptoms. They were 43 females and 17 males with mean age 52.6 ± 5.1 years and disease duration of 26 ± 2.4 months. Group 1 included those patients on MTX (mean dose 20.5 mg/week, mean duration 27.2 ± 5.2 months), and group 2 included 25 patients using only NSAIDs intermittently for a mean duration of 20.5 ± 1 months. The baseline clinical and laboratory of both groups are shown in Table 1 and all showed no statistical significant differences. In this study 23 patients (38.3%) had subclinical ILD (RA-ILD); 15 (65.2%) patients were from group 1 and 8 from group 2 (34.8%), while the remaining 37 patients (61.7%) did not meet the HRCT criteria for diagnosing ILD and were therefore designated as RAno ILD. Table 2 shows that the percent of patients with RA-ILD, as evident by the abnormalities in HRCT, was more in group 1 than in group 2 (42.9% and 32% respectively), however this difference was insignificant. Ground glass opacities and septal thickening were the most common (80.5% and 66.7% respectively) while honeycombing was observed in 62.7% of RA-ILD patients. HRCT score revealed minimal to mild involvement in both groups (mean 1.5 vs 0.8, p > 0.05). Patients in group 1 had more pulmonary dysfunction results in terms of lower means of percent predicted FVC, TLC, FEV1, and DL CO , than those in group 2; though, these differences were statistically insignificant (see Figs. 1-3) . Table 3 shows that 6/22 patients (27.2%) with short disease duration (mean of 15 months) had HRCT evidence of ILD vs 17/38 patients (44.7%) with long disease duration (mean of 50 months); this difference was insignificant. Regarding PFT, 6 patients (27.2%) with short-disease duration had functional Table 4 shows that, apart from the mean disease duration, there were no significant differences between RA-ILD patients in either groups and those with RA-no ILD regarding clinical, laboratory or functional data. Table 5 shows a multinomial logistic regression analysis, which indicated a strong association of ILD with age (>60; relative risk ratio, 4.31; p < 0.05). Anti-CCP and RF titers showed a trend toward association with ILD (relative risk ratio, 3.6 and 3.15 respectively; p < 0.05). Age, gender, MTX intake, SDAI and smoking were insignificantly associated with ILD (p > 0.05). The presence of ILD was strongly associated with disease duration (relative risk ratio, 7.67; p < 0.001). FVC < 80% of predicated) showed a trend toward a negative association with ILD (relative risk ratio, 3.98; p < 0.05).
Discussion
In the last years, it is becoming increasingly evident that RA-ILD is a more prominent and debilitating manifestation of RA than formerly believed. There are many factors that can obscure the diagnosis, however early diagnosis and treatment may delay the progression to end-stage lung disease. Diagnosis can be difficult since patients are unlikely to report dyspnea due to the decrease in physical activity with advanced arthritic symptoms. Recently, there has been increasing recognition of the importance of respiratory disease in patients with rheumatoid arthritis. Notably, interstitial lung disease is the only complication of RA increasing in prevalence and accounts for approximately 6% of all RA deaths [21] .
Our results revealed that 38.3% (23/60) of all included RA patients had subclinical RA-ILD, while 61.7% (37/60) did not have ILD (RA-no ILD). All RA-ILD cases had highresolution CT abnormalities characteristic of ILD despite lacked chest manifestations. However, only 16 patients (26.7%) had abnormal PFT and 12 (20%) had abnormal chest radiography. Accordingly, normal chest examination, CXR, PFT report cannot exclude ILD in patients with RA and we are still in need for HRCT. Furthermore, abnormalities on chest examination, PFTs with restrictive changes or chest Xrays should prompt physicians to request a chest HRCT scan. In our study, based on comparative analysis of clinical, laboratory and functional variables between RA-ILD and RA-no ILD patients, long-standing disease with mean articular duration more than 50 months carries a significant risk for ILD. Other variables as age, gender, smoking, disease activity, or RF seropositivity were not significant risk factors for development of RA-ILD. In the study of Gochuico et al. [22] , chest HRCT identified preclinical ILD in 21/64 (33%) asymptomatic RA patients. They found that physical examination and PFT measurements were not sensitive methods of detecting preclinical ILD, however, they observed that the history of smoking could be a potential risk factor for its development. Karazincir et al. [23] also, investigated the pulmonary involvement by HRCT in 25 RA patients who are asymptomatic and lifelong non-smoker, Chest X-ray, PFT and HRCT findings showed 12%, 16% and 48% abnormalities respectively. They found no significant correlation between HRCT findings and disease activity, RF positivity, PFT results and disease duration. In the study of Chen et al. [24] the overall prevalence of radiologically defined RA-ILD in RA patients was high (61%) though the frequency of clinically evident ILD was only Table 4 Comparison of demographic features, disease activity, immune profile and PFT between RA patients with and without ILD. Variable RA patients (n = 60) 6%. They found that older age, long-standing disease, and higher disease activity represent risk factors for the development of RA-ILD.
In this study we revealed that spirometry alone may be an inadequate screening tool for subclinical ILD, and early functional changes could be achieved with a complete set of PFTs with lung volumes and DL CO to establish the diagnosis. Our study showed that patients with subclinical ILD had significant reductions in DL CO compared with those without. Similar results were found by Diaz de Leon et al. [25] and comparable findings were also present in a Japanese lung cancer screening study [26] , which demonstrated that subclinical ILD was associated with a significant decline in DL CO .
The first-line DMARD in RA is MTX. However, serious toxicity from MTX may affect the lungs, liver, and bone marrow. In our study, we found that 25% of RA patients on MTX had RA-ILD in comparison to 13.3% of those patients on NSAIDs only. Additionally, patients on MTX had more HRCT abnormalities than those in group 2, however this difference was not significant. Ground glass opacities and septal thickening were the most common (80.5% and 66.7% respectively), while honeycombing was observed in 62.7% of RA-ILD patients. We found also a non-significant difference in PFT between RA patients on MTX and those not; the probability that the changes may be related to the lung disease associated with RA rather than to methotrexate therapy cannot be excluded.
Several studies agreed with our results; Zou et al. [27] , studied 110 Chinese RA patients (79 women and 31 men) and ILD was found in 47 (42.73%) according to the HRCT, however honeycombing and subpleural nodules were more common in patients on MTX. A study done by Gochuico et al. [22] identified preclinical ILD in 21/64 patients (33%) having RA by HRCT. They concluded that treatment using MTX may be a risk factor for progression of preclinical ILD. Pappase et al. [28] studied 158 RA patients and found that 7.6% had PFT abnormalities consistent with restrictive lung disease. Notably, the majority of patients (68%) were receiving MTX. On the other hand, Dawson et al. [29] have reported an interesting study concerning the chronic pulmonary effects of MTX in RA patients there was no evidence of an association. Interestingly, in patients with pulmonary fibrosis, MTX did not cause any deterioration in pulmonary function over a 2-yr period. In another study of Sathi et al. [30] , MTX has not been shown to accelerate the progression of underlying ILD in RA [15] .
In conclusion, subclinical lung involvement should always be considered in RA patients particularly those on MTX. Pulmonary function tests supported by HRCT are necessary to improve the detection of ILD in asymptomatic RA patients. Further studies evaluating the potential effect of MTX on progressive ILD associated with RA are needed. 
